CVKD (Cadrenal Therapeutics) Research & Development: $3.20 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVKD Cadrenal Therapeutics Inc CVKD
26 GF Score
Price $2.03
! 2 Warning Signs
View Full Analysis

What is Cadrenal Therapeutics Research & Development?

Cadrenal Therapeutics CVKD +2.01% 26 Research & Development is $3.20 Mil as of Mar. 2026. GuruFocus rates CVKD with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cadrenal Therapeutics's Research & Development for the three months ended in Mar. 2026 was $0.77 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $3.20 Mil.

Cadrenal Therapeutics  (NAS:CVKD) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cadrenal Therapeutics Research & Development Related Terms

Cadrenal Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Cadrenal Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cadrenal Therapeutics Research & Development Chart

Cadrenal Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Research & Development
0.00 4.08 4.21 4.10

Cadrenal Therapeutics Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.67 1.08 0.69 0.67 0.77
CVKD
26GF Score
Cadrenal Therapeutics Inc CVKD
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cadrenal Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.20 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $3.20 Mil mean?
Cadrenal Therapeutics (CVKD) has a Research & Development of $3.20 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cadrenal Therapeutics and its competitors.
Is Cadrenal Therapeutics' Research & Development too high?
Cadrenal Therapeutics' current Research & Development is $3.20 Mil. Overall, Cadrenal Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Cadrenal Therapeutics' Research & Development compare to RVPH and IMNN?
Cadrenal Therapeutics' Research & Development of $3.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cadrenal Therapeutics and its competitors. Cadrenal Therapeutics's current Research & Development is $3.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cadrenal Therapeutics stock overvalued right now?
Cadrenal Therapeutics (CVKD) has a current Research & Development of $3.20 Mil. The current Research & Development is $3.20 Mil. Cadrenal Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cadrenal Therapeutics (CVKD), the current Research & Development is $3.20 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cadrenal Therapeutics Business Description

Address 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
26GF Score

Get the complete analysis for CVKD

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.03
Price